Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025

Details of the Poster Presentations:ATG-201 (CD19 x CD3 TCE)Title: ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune DiseasesAbstract Number: 0001Session: (0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster IDate:Sunday, October 26Time: 10:30 AM - 12:30 PM (Central Time)           00:30 AM - 02:30 AM, October 27 (Beijing Time) Details of the Poster Presentations: ATG-201 (CD19 x CD3 TCE) ...

Details of the Poster Presentations:
ATG-201 (CD19 x CD3 TCE)
Title: ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Abstract Number: 0001
Session: (0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I
Date:Sunday, October 26
Time: 10:30 AM - 12:30 PM (Central Time)
           00:30 AM - 02:30 AM, October 27 (Beijing Time)

Forward-looking Statements:
For details on forward-looking statements, please refer to our full Interim Results press release on the Company's website: https://www.antengene.com/newsinfo/442

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: [email protected]  
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: [email protected] 
Mobile: +86 13062747000

Logo - https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/antengene-to-present-latest-preclinical-results-from-atg-201-cd19xcd3-tce-at-acr-2025-302561416.html